http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-070581-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_37f4922dfb7777b019e504b885211b8e http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0a9e6421e9257148abad101e1ce6c162 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_87343f0391f5074a8ffb73f681e41648 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-37 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-357 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P33-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-427 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-426 |
| filingDate | 2009-02-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e392be37bbc26a978d76f24005bdf55b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_12c13d96b32cfc66af31e4901e04a8f7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8bdab544cfc47decbb2482b3bd27831b |
| publicationDate | 2010-04-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-070581-A1 |
| titleOfInvention | ASSOCIATION BETWEEN A BIS-TIAZOLIO SALT OR ONE OF ITS PRECURSORS AND ARTEMISININE OR ONE OF ITS DERIVATIVES FOR THE TREATMENT OF SERIOUS PALUDISM |
| abstract | A pharmaceutical composition comprising at least one bis-thiazolium salt, compound of formula (1) or one of its precursors, and artemisinin or one of its derivatives. The use of said association for the preparation of a medicament intended for the treatment or prevention of severe malaria. A kit for the treatment or prevention of severe malaria. Claim 1: Association, comprising as active ingredients a bis-thiazolium salt, compound of formula (1) in which Rb represents a group R1 representing a hydrogen atom, a C1-5 alkyl radical, optionally substituted with a radical aryl (mainly a phenyl radical), a hydroxy, an alkoxy, in which the alkyl radical comprises 1 to 5 carbon atoms, or aryloxy (mainly phenoxy), or a T group, T representing the group of formula (2 ) in which R2 represents a hydrogen atom, a C1-5 alkyl radical or a -CH2-COO-C1-5 alkyl group; R3 represents a hydrogen atom, a C1-5 alkyl or alkenyl radical, if necessary substituted with -OH, a phosphate group, an alkoxy radical, wherein the alkyl radical is C1-3, or aryloxy; or an alkyl or (aryl) carbonyloxy group; or even R2 and R3 together form a cycle of 5 or 6 carbon atoms; R2 and R3 may be linked to form a cycle or a heterocycle of 5 to 7 links, possibly comprising one or more heteroatoms of O and / or S; Z represents a C6-21 alkyl radical, mainly from C12 or C13 to C21, if necessary with the insertion of one or more multiple bonds, and / or one or more heteroatoms of O and / or S, and / or one or more aromatic cycles, and pharmaceutically acceptable salts of these compounds, with the proviso that Z does not represent a C6-8 alkyl radical, when Rc, Rd, R2 and R3 represent a methyl radical, or when Rc and Rd on the one hand, and R2 and R3 on the other hand, together form aromatic cycles of 6 carbon atoms; Rd represents R2 as defined above or P, P representing the group of formula (3); Rc represents R3 as defined above or U, U representing the group of formula (4) with Rb = T being understood, if Rc = R3 and Rd = R2; Rd = P, if Rc = R3 and Rb = R1; and Rc = U, if Rb = R1 and Rd = R2; in the form of a free base, salt, hydrate or solvate, or one of its precursors, and artemisinin or one of its derivatives, for the treatment and / or prevention of severe malaria. Claim 6: Pharmaceutical composition according to claim 5, characterized in that the bis-thiazolium salt, compound of formula (1) is 1,12-dodecamethylenebis dibromide [4-methyl-5- (2-hydroxyethyl) thiazolium]. Claim 7: Pharmaceutical composition according to claim 5 or claim 6, characterized in that the artemisinin derivative is artesunate. Claim 8: Pharmaceutical composition according to any one of claims 5 to 7; characterized in that it is adapted for oral, rectal or injectable administration, and preferably adapted for intravenous injection, particularly in the form of perfusion. |
| priorityDate | 2008-02-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 38.